Clinical trials: Hepatitis C Virus (HCV)
Chronic Hepatitis C
Efficacy and Safety of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P08034)
This is a three-part (Part A, Part B, and Part C), open-label, multicenter study of boceprevir in pediatric participants with chronic hepatitis C (CHC) genotype 1 (GT1).
- Trial name
- NCT01590225
- Testing
- Boceprevir, Peginterferon alpha-2b, Ribavirin
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
The Sublimated Mare Milk Supplement in Hepatitis C
This clinical trial studies the effect of sublimated mare milk supplement on patients with hepatitis C.
- Trial name
- NCT03669835
- Testing
- Mare milk supplement, Standard therapy
- Where
- Kazakhstan
- Volunteers
- 100 people
- Sponsor
- Asfendiyarov Kazakh National Medical University
Hepatitis C
Investigation Of The Effect Of Steady State Filibuvir On The Pharmacokinetics Of Oral Contraceptives (Levonorgestrel And Ethinyl Estradiol)
The purpose of this study is to estimate the effect of filibuvir on the pharmacokinetics of ethinyloestradiol [EE] and levonorgestrel [LN], to assess the safety and tolerability of 600 mg BID of filibuvir in healthy women and to…
- Trial name
- NCT00918476
- Testing
- filibuvir + Oral Contraceptives
- Where
- Belgium
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hepatitis C Virus Infection
Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of sofosbuvir/velpatasvir (SOF/VEL) fixed dose combination (FDC) for 12 weeks in adults with chronic genotype 1, 2, 4, 5, or 6 hepatitis…
- Trial name
- ASTRAL-1 (NCT02201940)
- Testing
- SOF/VEL
- Where
- 80 sites in United States, Belgium and 7 more
- Volunteers
- 741 people
- Sponsor
- Gilead Sciences
Hepatitis C Virus Infection
Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 1 Hepatitis C Virus Infection Patients
This study was to assess the safety and efficacy of Seraprevir in combination with sofosbuvir administered for 12 weeks in patients with Hepatitis C (HCV) genotype1.
- Trial name
- NCT04001608
- Testing
- Seraprevir, Sofosbuvir
- Where
- 22 sites in China
- Volunteers
- 206 people
- Sponsor
- Ginkgopharma CO., LTD
Hepatitis C
Use of Omega-3 Fatty Acids (Fish Oil) in Patients With Chronic Hepatitis C Infection
Hepatitis C virus infection is the most common blood-borne infection in the United States and is a leading cause of chronic liver disease affecting 130 million people around the world.
- Trial name
- NCT00547716
- Testing
- Omega-3 Fatty Acids
- Where
- 2 sites in United States
- Sponsor
- University of Missouri, Kansas City
Hepatitis C
Reaching mEthadone Users Attending Community pHarmacies With HCV
Hepatitis C Virus (HCV) is a blood-borne virus that damages the liver and is a major public health threat globally. Most individuals infected with HCV are unaware of it and show no symptoms until presenting with incurable, fatal…
- Trial name
- REACH-HCV (NCT03935906)
- Testing
- Reach Pathway, Education-only Pathway
- Where
- 3 sites in Australia, United Kingdom
- Volunteers
- 1,410 people
- Sponsor
- University of Dundee
Chronic Hepatitis C
Ezetimibe as a Safe and Efficacious Treatment for Chronic Hepatitis C
To address the need for more affordable hepatitis C virus (HCV) antivirals with high barriers to viral resistance and strategies to shorten the current treatment duration, the goal is to develop affordable therapeutic regimens to…
- Trial name
- NCT02971033
- Testing
- 20mg ezetimibe, 40mg ezetimibe
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- VA Office of Research and Development
Hepatitis C Recurrence After Liver Transplant
The Impact of Everolimus Based Immunosuppression in the Evolution of Hepatitis C Fibrosis After Liver Transplantation
Background: Hepatitis C recurrence, which invariably occurs in viremic liver transplant (LT) recipients, associated with accelerated liver fibrosis leading to established graft cirrhosis in 40-20% of patients in 5 years with…
- Trial name
- NCT01707849
- Testing
- EVL arm, MMF arm
- Where
- Spain
- Volunteers
- 18 people
- Sponsor
- Hospital Vall d'Hebron
Hepatitis C, Chronic
An Observational Study of Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) on Predictive Values of RVR on Sustained Virological Response in Different Stages of Liver Fibrosis in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1
This observational study will evaluate the predictive value of rapid virological response (RVR) and early virological response (EVR) on sustained virological response (SVR) by stage of liver fibrosis in treatment-naïve patients…
- Trial name
- NCT01750216
- Where
- 14 sites in Poland
- Volunteers
- 196 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic
A Study of Combination Treatment With an HCV Polymerase Inhibitor (RO5024048) and an HCV Protease Inhibitor (RO5190591/Danoprevir) in Genotype 1 Chronic Hepatitis C Patients
This 7 cohort study will evaluate the efficacy and safety of combination treatment with an HCV nucleoside polymerase inhibitor(RO5024048)and an HCV protease inhibitor(RO5190591/ITMN-191/danoprevir) in patients with chronic…
- Trial name
- NCT00801255
- Testing
- RO5024048, danoprevir
- Where
- 5 sites in Australia, New Zealand
- Volunteers
- 88 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Liver Disease
Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve Patients
This study will explore the relationship of different DEB025 doses in combination with RBV to pharmacokinetic, pharmacodynamic (i.e.
- Trial name
- NCT01970904
- Testing
- Alisporivir, Ribavirin, Peg-IFNα2a
- Where
- 25 sites in Germany, Poland and 2 more
- Volunteers
- 147 people
- Sponsor
- Debiopharm International SA
Hepatitis C, Chronic
Model Towards Elimination of Hepatitis C Infection in Egypt: Feasibility and Effectiveness in 73 Villages
Background: The global response to the HCV infection epidemic has been transformed by the availability of low-cost curative short course direct acting antiviral (DAA) therapy.
- Trial name
- NCT04177043
- Testing
- HCV antibody and hepatitis B surface antigen (HBsAg) rapid diagnostic tests, DAAs
- Volunteers
- 221,855 people, healthy volunteers welcome
- Sponsor
- Egyptian Liver Hospital
HIV Testing, HEPATITIS C (HCV)
Rapid HIV, Hep C, and Syphilis Screening in a Rural Street Medicine Clinic
West Virginia faces rising rates of HIV, hepatitis, and syphilis, particularly among individuals experiencing homelessness, substance use, and mental health challenges.
- Conditions
- HIV Testing, HEPATITIS C (HCV), Syphilis, Hepatitis B Virus (HBV)
- Trial name
- NCT07317687
- Testing
- Rapid Fingerstick Test, Blood Draw for lab test
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- West Virginia University
Hepatitis C
Study of CTS-1027 in Combination With Pegylated Interferon and Ribavirin in Hepatitis C Virus (HCV) Null-Responders
The purpose of this study is to determine if the combination treatment of CTS-1027, pegylated interferon and ribavirin can improve the response rates in HCV patients who did not previously respond to pegylated interferon and…
- Trial name
- CTS-1027-04 (NCT01051921)
- Testing
- CTS-1027, Pegylated interferon, Ribavirin
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 67 people
- Sponsor
- Conatus Pharmaceuticals Inc.
Hepatitis C Virus, Advanced Fibrosis
Study of Long-term Peg Intron vs. Colchicine in Non-responders.
In this study Peg-Intron will be tested to see if it will give better results than Colchicine. At this time, there is currently no recommended maintenance treatment for patients who have failed to respond to…
- Conditions
- Hepatitis C Virus, Advanced Fibrosis, Cirrhosis
- Trial name
- COPILOT (NCT00179413)
- Testing
- PEG -Intron, Colchicine
- Where
- 49 sites in United States
- Volunteers
- 549 people
- Sponsor
- Beth Israel Deaconess Medical Center
Chronic Hepatitis C
Hansenula-derived Pegylated Interferon in Treatment of Patients With Chronic Hepatitis C
It is a multi-center study of the efficacy of a new Pegylated Hansenula-derived recombinant interferon α 2a (Reiferon Retard® 160 µg once weekly in combination with ribavirin in treatment of Egyptian patients with chronic…
- Trial name
- HAPIC (NCT01649245)
- Testing
- Reiferon retard
- Where
- Egypt
- Volunteers
- 5,000 people
- Sponsor
- MinaPharm Pharmaceuticals
Hepatitis C, HIV
Determination of HCV Prevalence in a HIV Patient Cohort in Phnom Penh, Cambodia
Hepatitis C (HCV) is an important global public health problem, disproportionately affecting HIV positive populations. Asia and Africa account for most of the co-infection burden, but access to HCV screening and treatment is…
- Trial name
- HCV-Epi (NCT02361541)
- Testing
- HCV screening
- Where
- Cambodia
- Volunteers
- 3,045 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Chronic Hepatitis C
A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus
The purpose of this study is to explore the efficacy and safety of TMC647055, TMC435, and low-dose ritonavir, administered together with and without ribavirin and of TMC647055, TMC435, low-dose ritonavir administered together…
- Trial name
- NCT01724086
- Testing
- TMC647055, TMC435, Ritonavir
- Where
- 10 sites in Belgium, Germany
- Volunteers
- 90 people
- Sponsor
- Janssen R&D Ireland
Chronic Hepatitis C Virus (HCV) Infection
An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation
The purpose of this study is to evaluate the effectiveness of telaprevir in combination with Peg-IFN-alfa-2a and ribavirin in stable liver transplant patients with chronic hepatitis C virus (HCV) genotype 1.
- Trial name
- REPLACE (NCT01571583)
- Testing
- Telaprevir, Pegylated interferon alfa-2a, Ribavirin
- Where
- 21 sites in Austria, Belgium and 4 more
- Volunteers
- 74 people
- Sponsor
- Janssen-Cilag International NV
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.